• Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Antibody-Drug Conjugates: The 21st Century Magic Bullets for Cancer

Antibody-Drug Conjugates: The 21st Century Magic Bullets for Cancer

Hardcover

Series: Aaps Advances in the Pharmaceutical Sciences, Book 17

Medical ReferenceChemistry

ISBN10: 3031830040
ISBN13: 9783031830044
Publisher: Springer
Published: Apr 16 2025
Pages: 299
Weight: 1.35
Height: 0.75 Width: 6.14 Depth: 9.21
Language: English

The field of antibody-drug conjugates (ADCs) has undergone remarkable advancements in recent years, marked by significant progress in both drug approvals and ongoing clinical development. Since the approval of the first ADC in 2010 (gemtuzumab ozogamicin, Mylotarg(R)), the landscape has expanded dramatically. Today, there are 11 FDA-approved ADCs, targeting a variety of cancers across multiple indications. The approved ADCs include a range of payloads, linkers, and antibodies, each optimized for a variety of specific therapeutic targets. The increasing diversity of ADCs reflects the growing potential of these innovative treatments to address a wide array of malignancies, from hematologic cancers to solid tumors.

Also in

Medical Reference